drugset / Trial / NCT05116774
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the efficacy and safety of BCX9930 monotherapy for the treatment of PNH compared to continued C5 inhibitor therapy in adult PNH participants with residual anemia despite treatment with a C5 inhibitor.
Timeline
- Start
- 2021-12-06
- Primary completion
- 2023-09-14
- Completion
- 2023-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCX9930 | Unknown | 400 mg | Oral |
| Comparator | Eculizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Ravulizumab | Monoclonal antibody | — | Intravenous |